Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Assets Average (2017 - 2025)

Vistagen Therapeutics' Assets Average history spans 10 years, with the latest figure at $73.0 million for Q4 2025.

  • For Q4 2025, Assets Average fell 25.06% year-over-year to $73.0 million; the TTM value through Dec 2025 reached $73.0 million, down 25.06%, while the annual FY2025 figure was $104.0 million, N/A changed from the prior year.
  • Assets Average for Q4 2025 was $73.0 million at Vistagen Therapeutics, down from $74.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $127.4 million in Q1 2024 and bottomed at $28.6 million in Q3 2023.
  • The 4-year median for Assets Average is $95.5 million (2021), against an average of $89.7 million.
  • The largest annual shift saw Assets Average soared 1859.38% in 2021 before it plummeted 35.39% in 2025.
  • A 4-year view of Assets Average shows it stood at $95.5 million in 2021, then fell by 9.3% to $86.6 million in 2023, then grew by 12.43% to $97.4 million in 2024, then decreased by 25.06% to $73.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Assets Average are $73.0 million (Q4 2025), $74.9 million (Q3 2025), and $76.6 million (Q2 2025).